

RECEIVED
CENTRAL FAX CENTER
JUN 14 2011

PTO/SB/81 (01-09)

Approved for use through 11/30/2011. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY OR REVOCATION OF POWER OF ATTORNEY WITH A NEW POWER OF ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS		Application Number	See attached Schedule A
		Filing Date	See attached Schedule A
		First Named Inventor	See attached Schedule A
		Title	See attached Schedule A
		Art Unit	See attached Schedule A
		Examiner Name	See attached Schedule A
		Attorney Docket No.	See attached Schedule A

I hereby revoke all previous powers of attorney given in the above-identified application.

 A Power of Attorney is submitted herewith.

OR

 I hereby appoint Practitioner(s) associated with the following Customer Number as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith:

23483

OR

 I hereby appoint Practitioner(s) named below as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith:

Practitioner(s) Name	Registration Number	Practitioner(s) Name	Registration Number

Please recognize or change the correspondence address for the above-identified application to:

 The address associated with the above-mentioned Customer Number:

OR

 The address associated with Customer Number:

OR

 Firm or Individual Name

Address			
City	State	Zip	
Country	Telephone	Email	

I am the:


 Applicant/Inventor.

OR

 Assignee of record of the entire interest. See 37 CFR 3.71.

Statement under 37 CFR 3.73(b) (Form PTO/SB/96) submitted herewith or filed on _____

SIGNATURE of Applicant or Assignee of Record

Signature		Date	June 6, 2011
Name	Richard Bagley	Telephone	617-259-1970
Title and Company	President, COO, CFO	, ZIOPHARM Oncology, Inc.	

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

Total of 1 forms are submitted.

RECEIVED 4/5
CENTRAL FAX CENTER
JUN 14 2011

PTO/SB/96 (07-09)

Approved for use through 07/31/2012. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: See Attached Schedule AApplication No./Patent No.: See Attached Schedule A Filed/Issue Date: See Attached Schedule ATitled: Isophosphoramido Mustard Analogs and Use ThereofZIOPHARM Oncology, Inc., a Corporation

(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

- the assignee of the entire right, title, and interest in;
- an assignee of less than the entire right, title, and interest in
(The extent (by percentage) of its ownership interest is _____ %); or
- an assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made) the patent application/patent identified above by virtue of either:

A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:


1. From: See Attached Schedule A To: See Attached Schedule A
The document was recorded in the United States Patent and Trademark Office at Reel Schedule a, Frame Schedule a, or for which a copy thereof is attached.
2. From: See Attached Schedule A To: See Attached Schedule A
The document was recorded in the United States Patent and Trademark Office at Reel Schedule a, Frame Schedule a, or for which a copy thereof is attached.
3. From: See Attached Schedule A To: See Attached Schedule A
The document was recorded in the United States Patent and Trademark Office at Reel Schedule a, Frame Schedule a, or for which a copy thereof is attached.

Additional documents in the chain of title are listed on a supplemental sheet(s).

As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.


 Signature

June 6, 2011

Date

President, COO, CFO

 Richard Bagley
 Printed or Typed Name

Title

Attorney Docket No.: ZIPH-009-102

Application #: 10686809 Filing Dt: 10/17/2003 Patent #: 7452910 Issue Dt: 11/18/2008

PCT #: NONE Publication #: US20040171668 Pub Dt: 09/02/2004

Inventors: Bernd Nickel, Gerald Bacher, Thomas Klenner, Thomas Beckers, Peter Emig, Erik Bruyneel, Gunter Kamp, Kirsten Peters, Jürgen Engel

Title: INDOLYL-3-GLYOXYLIC ACID DERIVATIVES HAVING THERAPEUTICALLY VALUABLE PROPERTIES

Reel/Frame:	019720 / 0655	Received:	08/20/2007	Recorded:	08/20/2007	Mailed:	08/21/2007	Pages:
-------------	---------------	-----------	------------	-----------	------------	---------	------------	--------

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignors:	NICKEL, BERND	Exec Dt: 02/16/2000
	BACHER, GERALD	Exec Dt: 02/16/2000
	KLENNER, THOMAS	Exec Dt: 02/16/2000
	BECKERS, THOMAS	Exec Dt: 02/16/2000
	EMIG, PETER	Exec Dt: 02/16/2000
	ENGEL, JURGEN	Exec Dt: 02/23/2000
	BRUYNEEL, ERIK	Exec Dt: 02/18/2000
	KAMP, GUNTER	Exec Dt: 02/22/2000
	PETERS, KIRSTEN	Exec Dt: 02/22/2000

Assignee:	ASTA MEDICA AKTIENGESELLSCHAFT
	AN DER PIKARDIE 10
	DRESDEN, GERMANY D-01277

Reel/Frame:	019714 / 0687	Received:	08/20/2007	Recorded:	08/20/2007	Mailed:	08/21/2007	Pages:
-------------	---------------	-----------	------------	-----------	------------	---------	------------	--------

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignor:	ASTA MEDICA AKTIENGESELLSCHAFT	Exec Dt: 11/05/2001
Assignees:	BAXTER HEALTHCARE S.A.	
	HERTISTRASSE 2	
	WALLISELLEN, SWITZERLAND 8304	
	BAXTER INTERNATIONAL INC.	
	ONE BAXTER PARKWAY	
	DEERFIELD, ILLINOIS 60015	

Reel/Frame:	019714 / 0701	Received:	08/20/2007	Recorded:	08/20/2007	Mailed:	08/21/2007	Pages:
-------------	---------------	-----------	------------	-----------	------------	---------	------------	--------

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignors:	BAXTER HEALTHCARE S.A.	Exec Dt: 07/25/2007
	BAXTER INTERNATIONAL, INC.	Exec Dt: 07/25/2007

Assignee:	ZIOPHARM ONCOLOGY, INC.
	SUITE 300, FLAGSHIP WHARF
	197 EIGHTH STREET
	CHARLESTOWN, MASSACHUSETTS 02129

26820773_1